

## FEDERAL REGULATIONS RESOURCES

### SAMHSA Resources

The Substance Abuse and Mental Health Services Administration (SAMHSA) within the U.S. Department of Health and Human Services, through their Center for Substance Abuse Treatment (CSAT), includes the mission of promoting community-based substance abuse treatment and recovery services for individuals and families. SAMHSA's goals include improving access, reducing barriers, and promoting high quality, effective treatment and recovery services.

- [SAMHSA's Buprenorphine Physician and Treatment Program Locator](#) A directory of treatment programs and physicians authorized to treat patients with buprenorphine (Source: SAMHSA)
- [SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program](#) Reports how SAMHSA evaluates the buprenorphine waiver program (Source: SAMHSA)
- [SAMHSA Medication Assisted Treatment Website](#) Provides information about buprenorphine, including resources, the waivering process, DATA 2000, and the latest news (Source: SAMHSA)
- [SAMHSA Provider Waiver Qualifications](#) Information from the CSAT Buprenorphine Information Center on the criteria required to receive waiver under DATA 2000 (Source: SAMHSA)

### Laws and Requirements

- [42 CFR Part 8 – Medication Assisted Treatment for Opioid Use Disorders](#) Legal overview of MAT for opioid use disorders (Source: Cornell Law School)
- [AANP State Practice Environment](#) Nurse practice laws and regulations for each state on an interactive map (Source: AANP)
- [Applying the Substance Abuse Confidentiality Regulations 42 CFR Part 2](#) Contains frequently asked questions and answers in reference to applying substance abuse confidentiality regulations (Source: SAMHSA)
- [ASAM Summary of the Comprehensive Addiction and Recovery Act](#) Summarizes key features of CARA 2016 (Source: ASAM)
- [Comprehensive Addiction and Recovery Act of 2016](#) [PDF] The House of Representatives filing copy regarding CARA 2016 (Source: House.gov)
- [Confidentiality of Substance Use Disorder Patient Records](#) [PDF] Discusses the rules regarding keeping substance use disorder patient records confidential (Source: DHHS)
- [DATA 2000](#) This page provides links to the full text, summary, and physician waiver requirements under DATA 2000 (Source: SAMHSA)
- [Flowchart of Steps in Applying for DEA Registration](#) [PDF] Steps in Applying for DEA Registration (Source: Clinical Tools, Inc.)

- [Frequently Asked Questions Applying the Substance Abuse Confidentiality Regulations to Health Information Exchange \(HIE\)](#) [PDF] Frequently asked questions in regard to substance abuse confidentiality regulations (*Source: SAMHSA*)
- [H.R.6 – SUPPORT for Patients and Communities Act](#) This is the full text of the law itself as it was signed into effect on 10/24/18 (*Source: Congress.gov*)
- [Medical Recordkeeping](#) [PDF] A description of what should be included in a buprenorphine patient's medical record (*Source: Clinical Tools, Inc.*)
- [Pharmacy Consent Form for Buprenorphine Treatment](#) [PDF] Provides an example pharmacy consent form that can be used by your provider (*Source: Clinical Tools, Inc.*)

### Additional Resources

- [Buprenorphine and Buprenorphine plus Naloxone \(en Español\)](#) La buprenorfina sublingual, y la buprenorfina y naloxona. This patient education resource addresses common questions about buprenorphine treatment for opioid dependence (*Source: MedlinePlus*)
- [Schedule of Opioids](#) [PDF] A table showing the schedule of opioids (*Source: Clinical Tools, Inc.*)